WO2000061190A2 - Treatment of intracellular infection - Google Patents
Treatment of intracellular infection Download PDFInfo
- Publication number
- WO2000061190A2 WO2000061190A2 PCT/GB2000/001350 GB0001350W WO0061190A2 WO 2000061190 A2 WO2000061190 A2 WO 2000061190A2 GB 0001350 W GB0001350 W GB 0001350W WO 0061190 A2 WO0061190 A2 WO 0061190A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phage
- targeting moiety
- cell
- agent
- microorganism
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to an agent for causing lysis of a microorganism residing within a cell, to a method for preparing said agent, to compositions comprising said agent, and to the use of said agent.
- the agent of the present invention is suitable for the treatment of an intracellular infection by a microorganism.
- microorganisms are capable of forming intracellular infections. These include: infections caused by species of Salmonella, Yersinia, Shigella, Campylobacter and Chlamydia. Live Salmonella and Yersinia can survive within the cells of mucosa of the gastrointestinal tract and fibroblasts, provide antigenic material continuously into the blood circulation and stimulate chronic inflammation and lead to arthritis; infections caused by the survival of Legionella pneumophila within alveolar macrophages and epithelial cells; infections caused by the survival of Listeria monocytogenes within cell cytosol; infections caused by an intracellular protozoan Toxoplasma gondii; and infections caused by the intracellular survival of Bordetella species (macrophages), Staphylococcus aureus (epithelial cells) and Group B streptococci (macrophages) . Some of these infections are exclusively intracellular, others contain both intracellular and extracellular components. However, it is the intracellular survival cycle of bacterial infection which is suspected as a
- intracellular microorganisms are often not amenable to drug treatment regimes. Where drugs are available, this problem has been exacerbated by the development of multiple drug resistant microorganisms. For similar reasons, vaccine therapies are not effective against such intracellular microorganisms. Also, increased systemic concentration of antibiotics to improve bioavailability within cells may result in severe side effects.
- Mycobacteria tuberculosis This bacterium is responsible for causing the disease tuberculosis which is responsible for more than three million deaths a year world-wide. M.
- tuberculosis infects macrophage cells within the body. Soon after macrophage infection, most M. tuberculosis bacteria enter, persist and replicate within cellular phagosome vesicles, where the bacteria are sequestered from host defences and extracellular factors.
- Phage in particular bacteriophage, have been known for many years and have been employed as delivery vehicles in conventional treatment regiments for alleviating conditions associated with defective or aberrant cells.
- WO 98/05344 teaches the use of bacteriophage for delivering an exogenous gene, such as a therapeutic polynucleotide, to a mammalian cell.
- Targeting of the bacteriophage to a pre-selected cell is achieved by use of a targeting moiety linked to the bacteriophage, said targeting moiety effecting binding and initiating internalisation of the bacteriophage into the pre-selected cell.
- the exogenous genetic material can be transcribed and translated, thereby increasing the concentration of the therapeutic molecule encoded by the therapeutic polynucleotide in the target cell.
- Aberrant cell treatment regiments such as those disclosed in WO 98/05344 are conventionally known as gene therapy methods. Such regiments, however, do not address the problem and/or persistence of intracellular infections by microorganisms.
- WO 97/291 85 teaches the preparation of recombinant phages, and the use thereof in the treatment or prophylaxis of bacterial infections. According to WO 97/291 85, an anti-bacterial antibody is presented from an exposed surface of a bacteriophage, thereby rendering the bacteriophage capable of binding to and inhibiting growth of the targeted bacterial cell. WO 97/291 85 does not, however, teach how to combat intracellular infections by microorganisms.
- WO 99/1 0485 which teaches a bacteriophage system for identifying ligands susceptible to cell internalisation.
- Such ligands may provide suitable targets for bacteriophage gene delivery vehicles;
- WO 94/24959 which teaches a method of detecting compounds by utilising a chemically modified lambdoid bacteriophage.
- a bacteriophage is modified to form a phage-target molecule complex, said complex being non- infective.
- the target molecule Upon challenge with a molecule of interest, the target molecule is cleaved and the bacteriophage becomes infective.
- the presence of a molecule of interest may be detected by the presence of infective bacteriophage.
- WO 99/10485 or WO 94/24959 addresses problems associated with microbial infections, least of all the problem of combatting intracellular microbial infections.
- the present invention which, according to a first aspect, provides an agent for causing lysis of a microorganism residing within a target cell, comprising a targeting moiety capable of binding to a target cell and a phage associated with the targeting moiety, wherein following binding of the targeting moiety of the cell the phage enters the target cell and effects lysis of the microorganism residing within the target cell.
- targeting moiety means any structure which is capable of binding to the cell of interest. Examples include an antibody or fragment thereof, a receptor capable of binding to a ligand on the cell of interest, and a ligand capable of binding to a receptor on the cell of interest. Preferably, the targeting moiety is a ligand for a cell-surface receptor. Good results have been achieved in a specific embodiment of the invention using a transferrin molecule as targeting moiety.
- the targeting moiety need not demonstrate 1 00% specificity for the cell of interest, though naturally a degree of specificity is desirable for a highly efficient system.
- the targeting moiety may be capable of binding and internalisation, in which case the phage and targeting moiety may be delivered as a complex (ie.
- Identification of potential targeting moieties susceptible to internalisation may be achieved by, for example, conventional methods such as those disclosed in WO 99/1 0485, or on a trial-and-error basis.
- the targeting moiety may be capable of binding but not internalisation, in which case the phage alone may be delivered into the target cell.
- binding includes any interaction between the targeting moiety and the cell of interest which permits the phage to be delivered into the cell. This delivery process is one in which the whole phage enters the cell of interest. The targeting moiety may become separated from the phage during this delivery process. Without being bound by any theory, it is believed that binding involves the formation of a complex between the agent and a receptor present on the target cell. It is believed that formation of the complex induces internalisation of the agent via a receptor-mediated delivery mechanism such as that utilised by native eukaryotic viruses (eg . adenovirus) .
- native eukaryotic viruses eg . adenovirus
- association means any interaction between the targeting moiety and the phage such that the targeting moiety is capable of directing the phage to the cell of interest and when so directed the phage may be delivered into the cell.
- Any one phage may be associated with one or more targeting moieties. Where a given phage is associated with more than one targeting moiety, each such moiety may bind to a different cell-type. Alternatively, each targeting moiety preferably binds to the same cell-type, although each may recognise a different site on the same cell-type.
- lysis is used in this specification to include destruction of the microorganism through damage to or rupture of the microorganism cell wall. However, it is also intended to include any phage action which causes arrested growth and/or multiplication of the intracellular microorganism.
- the prior art bacteriophage vectors employed in gene therapy regiments are non- lytic towards microorganisms.
- Conventional gene therapy bacteriophage vectors are non-lytic towards microorganisms to ensure that the natural bacterial flora of a mammalian host are unaffected by the bacteriophage during gene transfer treatment regiments.
- conventional gene therapy bacteriophage are often rendered abortive to lytic growth prior to use in gene therapy regiments. This may be achieved, for example, by modifying bacteriophage tail proteins that are required for natural phage transduction so that the bacteriophage is non-functional in a prokaryotic host, or by otherwise rendering the bacteriophage incapable of mediating injection of genetic material into a eukaryotic host cell.
- the phage of the present invention are capable of natural phage transduction and of effecting lysis of a microorganism.
- the targeting moiety is a ligand for a cell-surface receptor and is physically or chemically associated with a phage.
- This phage-targeting moiety combination is administered to cells infected by an intracellular microorganism and the phage enters the cells and lyses microorganism within those cells.
- the phage may also enter that internal compartment or vesicle.
- the targeting moiety binds to an internal compartment or vesicle in the cell and within which the microorganism can reside.
- the targeting moiety may be a ligand for a cell surface receptor and also a ligand for a receptor on the surface of an internal compartment or vesicle.
- the presence of a targeting moiety for a receptor on the surface of an internal compartment or vesicle facilitates entry of the phage into the internal compartment or vesicle where, once inside, it may exert a lytic effect on the microorganism residing within the internal compartment or vesicle.
- the targeting moiety for a cell surface receptor and the targeting moiety for a receptor on the surface of an internal compartment or vesicle may be the same or different.
- the agents of the present invention may be modified such that the targeting moiety for the receptor on the internal compartment or vesicle is functional only following entry of the phage into a target cell. This may be achieved, for example, by employing a cell-specific promoter to ensure that the targeting moiety for the receptor on the surface of the internal compartment or vesicle is expressed only after the phage has been delivered to that specific cell-type.
- the targeting moiety for the receptor on the surface of the internal compartment or vesicle may be obscured (eg.
- the targeting moiety for the receptor on the surface of the internal compartment or vesicle may be made accessible (eg. by cleavage or other modification of the targeting moiety for the cell surface receptor) during the internalisation process following binding of the agent to the target cell.
- the phage of the present invention once the phage of the present invention has been delivered to the target cell of interest it remains as a separate entity and does not (or any part thereof) integrate into the target cell's genome.
- the phage contains substantially no exogenous (ie. non-phage) nucleic acid. In a further embodiment the phage contains substantially no exogenous nucleic acid other than that coding for the targeting moiety.
- the phage comprises substantially no exogenous therapeutic polynucleotides capable of mediating a therapeutic benefit in a recipient of the polynucleotide or product thereof.
- a "therapeutic polynucleotide product” refers to a molecule produced as a result of transcription or translation of the therapeutic polynucleotide.
- Therapeutic polynucleotide products include transcription products (eg. antisense mRNA and catalytic RNA), and translation products (eg. proteins or peptides) of the therapeutic polynucleotide.
- the targeting moiety may be chemically linked to the phage. This may be achieved, for example, via a linker molecule (eg. a short peptide) or by other covalent means, for example, via a disulphide bridge.
- the targeting moiety may be bound to any part of the phage.
- the fusion between a targeting moiety and a phage should impair neither the binding of the targeting moiety to the cell membrane receptor nor the binding of the phage to its bacterial receptor.
- the chemical linkage procedure should not significantly alter the binding site to the cell receptor, e.g. by altering its conformation or by imposing structural rigidity.
- the transferrin chemical linkage illustrated in the present application does not prevent its binding to its receptor.
- the selected targeting moiety preferably demonstrates conformational stability.
- the chemical linkage construct preferably places the targeting moiety at a distance from the phage body sufficient to provide the targeting moiety with a degree of rotational flexibility so as to preserve maximum interaction of the targeting moiety with its receptor.
- the preferred means for chemical linkage is heterofunctional crosslinking via a disulfide bridge.
- the targeting moiety may be physically mixed with the phage.
- the target moiety may become physically adsorbed to the phage by, for example, hydrogen-bonding, hydrophobic/hydrophilic bonding, van der Waal's forces, electrostatic forces or other charged associations.
- the phage may carry a negative surface charge and the targeting moiety would then preferably carry a positive surface charge.
- the phage carries a positive charge sufficient to bind to a more negatively charged targeting moiety.
- Tf transferrin
- One embodiment is first to introduce free sulfhydril groups (-SH) in the transferrin molecule which does not have such groups in its native state. This can be done, eg. by thiolation of one or more free amino groups of the transferrin molecule with a reagent (eg. 2-iminothiolane) which modifies these groups and introduces -SH groups at these positions (this leads to Tf-SH) .
- a reagent eg. 2-iminothiolane
- modification can be achieved that will not impair transferrin binding to its receptor.
- Preferably 5-10 SH groups per Tf molecule are so modified.
- modified transferrin is purified from the low molecule weight reagent by gel filtration, eg.
- the phage is pre-treated by mixing with a hetero-bifunctional cross-linking agent (eg. Sulfo-SMCC, sulphosuccinilimidyl 4-(N-maleimidomethyl)- cyclohexane-1 -carboxylate) which covalently binds to free -NH 2 groups on the phage, leaving in the solution phage having active maleimide groups which are able to react with a -SH group from the thiolated transferrin.
- a hetero-bifunctional cross-linking agent eg. Sulfo-SMCC, sulphosuccinilimidyl 4-(N-maleimidomethyl)- cyclohexane-1 -carboxylate
- the degree of phage modification may be controlled by the ratio of the crosslinking agent to phage.
- modified phage is isolated from the reaction mixture by gel filtration on Sepharose 6B column and concentrated by membrane filtration.
- Tf-SH is mixed with an activated phage and the product (Tf- S-S-linker-Phage) is again isolated from Tf-SH by gel filtration in the same column.
- the presence of non-reacted phage can be afforded since it can only enhance the biological activity of the final preparation.
- Tf-S-S-linker-Phage product can involve the activation of Tf free -NH 2 groups and cross-linking activated transferrin with - SH groups at the phage surface. The outcome of this process depends on the availability and accessibility of -SH groups at the phage surface.
- Tf-phage physical aggregate depends mainly on their electrostatic charge at the pH of the mixture (this is preferably taken as a physiological pH) .
- the present invention has application in the treatment of any microorganism within a cell.
- a phage capable of lysing the microorganism is identified and associated with a targeting moiety capable of directing the phage to the infected cell, preferably to a specific compartment of the infected cell which contains an infectious agent.
- the agent of the present invention may be employed to treat an intracellular infection by a virus or by a bacterium. In one embodiment, this may be achieved by selection of a targeting moiety which is the same as the receptor employed by the infectious agent of interest. The agent of the present invention would then follow the same intracellular route as the infectious agent.
- complement receptors CR1 and CR3 are known as a gate for M.
- tuberculosis infection and therefore complement components such as C2a and C3B are targeting moiety candidates for phage modification.
- Another candidate which can be internalised via CR3 is Bordetella pertussis haemaglutinin.
- Another group of targeting moieties comprises those used by infectious agents during their intracellular persistence and/or which are required for their replication. Transferrin is one example of such a moiety. This protein is required for providing M. tuberculosis with iron which is critical for the bacterium's intracellular survival.
- the present invention is suitable for treating a number of intracellular infections. These include infections caused by Salmonella, Yersinia, Shigella, Campylobacter and Chlamidia. Live Salmonella and Yersinia can survive within the cells of mucosa of the gastrointestinal tract and fibroblasts, provide antigenic material continuously into the blood circulation and stimulate chronic inflammation and lead to arthritis.
- infections caused by the survival of Legionella pneumophila within alveolar macrophages and epithelial cells infections caused by the survival of Listeria monocytogenes within cell cytosol; infections caused by an intracellular protozoan Toxoplasma gondii; and infections caused by the intracellular survival of Bordetella species (macrophages), Staphylococcus aureus (epithelial cells) and Group B streptococci (macrophages) .
- Some of these infections are exclusively intracellular, others contain both intracellular and extracellular components. However, it is the intracellular survival cycle of bacterial infection which is suspected as a main supportive factor for disease progression.
- the present invention is also applicable for suppression of intracellular persistence, for example, within macrophages of other bacteria such as Leishmania donovani, Legionella pneumophila, Bordetella pertussis and other species of bordetellae, Group B streptococci, Salmonella species, Chlamydia and Borrelia burgdorferi. This can be achieved with the use of the macrophage- specific delivery moiety and a lytic bacteriophage specific for the microorganism.
- the present invention may be used against intracellular viruses. There may be an advantage in using a targeting moiety linked eg. to an antibody to a specific viral protein or to a short anti-sense DNA fragment. Such fusion construction may be delivered into a target cell as described previously.
- the phage for use in the agent of the present invention is a bacteriophage.
- Bacteriophages are phages which parasitise bacteria. They typically comprise a head containing genetic material (usually DNA, though occasionally RNA), enclosed by a wall of protein which is usually prolonged into a hollow tail.
- a bacteriophage initiates infection by attaching itself by its tail to the wall of a bacterial cell. Through enzyme action, the wall is perforated and bacteriophage genetic material passes through and into the bacterial cell.
- the bacteriophage genetic material then organises the bacterium to make more bacteriophage genetic material which assembles with bacteriophage head and tail to form assembled particles. These assembled particles are then released by lysis of the host bacterial cell.
- Bacteriophage are typically highly specific, with each kind of bacteriophage typically infecting only one bacterial species or strain.
- the bacteriophage is preferably a lytic bacteriophage.
- the bacteriophage is a mycobacteriophage.
- the mycobacteriophage is preferably specific for a particular species of mycobacteria.
- Most preferably the mycobacteriophage is selected from the group consisting of lytic mycobacteriophages L29, D34, DS-6A.
- the bacteria enter macrophages via receptor- mediated phagocytosis which may involve several mycobacteria-specific receptors on the macrophage membrane.
- receptor- mediated phagocytosis which may involve several mycobacteria-specific receptors on the macrophage membrane.
- the mycobacteria enter the early phagosome, arrest its maturation and sequester it from the terminal phagocytic organelles e.g lysosomes.
- mycobacteria form an intracellular infection within a vesicle of the macrophage and avoid the host cell's immune system.
- Mycobacteria infect monocytes and macrophages.
- that targeting moiety should bind to a monocyte and/or a macrophage.
- Suitable targeting moieties include Bordetella pertussis filamentous haemagglutinin which binds to complement receptor CR3 and can be internalised via a receptor-medicated endocytosis mechanism; complement component C3; antibody to C3 which can form an agent capable of binding to C3 in human sera and directing phage internalisation through the CR3 receptor; and ligands to macrophage receptors specific to mycobacteria (eg . mannose receptor, surfactant protein receptor, CD14 etc) which can bind receptors and be internalised.
- a transferrin molecule or a part thereof or a mutant or derivative thereof is a preferred targeting moiety.
- a method for preparing the agent according to the above definitions comprising contacting the targeting moiety and the phage such that the targeting moiety becomes associated with the phage.
- Phage stock may be produced by the infection of a liquid culture of M. tuberculosis or another auxiliary mycobacterium strain, removing cell debris by centrifugation, phage concentration (eg . by membrane filtration, PEG precipitation, centrifugation etc.,) followed by phage purification (eg. by gel filtration, additional membrane filtration etc.) from components (eg. proteins, polypeptides, salts, etc.) which can interfere with its chemical modification.
- This process can be easily scaled up by using filtration and chromatographic devices with required throughput.
- the stock of phage may then be mixed with the targeting moiety of interest.
- Transferrin is now illustrated simply as an example of a targeting moiety.
- the Tf-Phage complex appears stable under physiological conditions and it may be easily separated from the free Tf .
- the presence of free phage can be afforded since it will only enhance the biological activity of the preparation.
- the agent is prepared by bonding a targeting moiety to a phage. Examples of the preferred bonding procedure have been discussed above.
- a chimeric phage capable of causing lysis of a microorganism within a cell, comprising a targeting moiety capable of binding to the cell as part of a tail or coat protein of the phage.
- a method for preparing the chimeric phage described above Mycobacteriophages are illustrated as an example of this aspect of the present invention.
- mycobacteriophages which genomes have been fully sequenced and characterised (eg. phage L5 or d29)
- primers can be generated to identify DNA domains which encode "functionally silent" surface membrane proteins within the phage of interest. These can be excised and replaced with a DNA domain encoding the receptor binding moiety (eg. binding domain of transferrin) .
- novel "designed" chimeric phages may be produced which combine the replication function and the receptor binding function. Phages can be accumulated as discussed above and used as therapeutic agents against intracellular pathogens.
- composition comprising an agent of the present invention or a chimeric phage of the present invention, and a pharmaceutically acceptable carrier.
- the composition is preferably a liquid mixture of agent or chimeric phage and stabiliser which will stabilise the phage during storage in a nebuliser.
- the mixture may also contain another agent that will prevent phage aggregation.
- composition according to the present invention is provided in an aerosol form.
- Example 1 Modified Lytic anti-M. tuberculosis Phage as an Agent for the Treatment of Tuberculosis.
- This example describes the preparation of a lytic anti-M. tuberculosis phage (phage D34) that was modified either by absorption or chemically to carry a surface polypeptide that provides phage binding, internalisation and delivery into the phagosome within infected monocytes/macrophages. Once within the phagosome, the phage displays its lytic characteristics and either damages or lyses intraphagosomal mycobacteria.
- phage D34 lytic anti-M. tuberculosis phage
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/937,872 US6660264B1 (en) | 1999-04-09 | 2000-04-10 | Treatment of intracellular infection |
AT00919042T ATE270115T1 (en) | 1999-04-09 | 2000-04-10 | TREATMENT OF INTRACELLULAR INFECTION |
JP2000610522A JP2002541217A (en) | 1999-04-09 | 2000-04-10 | Treatment of intracellular infection |
CA002372078A CA2372078A1 (en) | 1999-04-09 | 2000-04-10 | Treatment of intracellular infection |
AU39798/00A AU772115B2 (en) | 1999-04-09 | 2000-04-10 | Treatment of intracellular infection |
EP00919042A EP1169063B1 (en) | 1999-04-09 | 2000-04-10 | Treatment of intracellular infection |
DK00919042T DK1169063T3 (en) | 1999-04-09 | 2000-04-10 | Treatment of intracellular infections |
DE60011880T DE60011880T2 (en) | 1999-04-09 | 2000-04-10 | TREATMENT OF INTRA-CELLULAR INFECTION |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9908195.2 | 1999-04-09 | ||
GBGB9908195.2A GB9908195D0 (en) | 1999-04-09 | 1999-04-09 | Treatment of intracellular infection |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000061190A2 true WO2000061190A2 (en) | 2000-10-19 |
WO2000061190A3 WO2000061190A3 (en) | 2001-03-01 |
Family
ID=10851274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/001350 WO2000061190A2 (en) | 1999-04-09 | 2000-04-10 | Treatment of intracellular infection |
Country Status (12)
Country | Link |
---|---|
US (1) | US6660264B1 (en) |
EP (1) | EP1169063B1 (en) |
JP (1) | JP2002541217A (en) |
AT (1) | ATE270115T1 (en) |
AU (1) | AU772115B2 (en) |
CA (1) | CA2372078A1 (en) |
DE (1) | DE60011880T2 (en) |
DK (1) | DK1169063T3 (en) |
ES (1) | ES2220451T3 (en) |
GB (1) | GB9908195D0 (en) |
PT (1) | PT1169063E (en) |
WO (1) | WO2000061190A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002034892A1 (en) * | 2000-10-25 | 2002-05-02 | Intercell Biomedizinische Forschungs- Und Entwicklungs Ag | Modified phage, comprising a non-lytic modification and expressing a kil-gene |
WO2003000274A2 (en) * | 2001-06-22 | 2003-01-03 | Phage Genomics Inc. | Bacteriophage preparation for the treatment of intracellular bacterial infection |
WO2003010316A1 (en) * | 2001-07-24 | 2003-02-06 | Phage Genomics Inc. | Bacteriophage-mediated lysis anthrax bacteria |
WO2003077953A2 (en) * | 2002-03-12 | 2003-09-25 | Phage Genomics Inc. | Bacteriophage composition |
EP1395273A1 (en) * | 2001-05-15 | 2004-03-10 | Page W. Faulk | Targeted delivery of drugs for the treatment of viral infections |
WO2004087924A2 (en) * | 2003-03-31 | 2004-10-14 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for delivery of substances to intracellular microorganisms |
JP2005523943A (en) * | 2002-04-27 | 2005-08-11 | ユニヴァーシティー オヴ ストラスクライド | Virus immobilization and stabilization |
DE10235967B4 (en) * | 2002-08-06 | 2005-09-08 | Bayer Healthcare Ag | Method for identifying substances with antimicrobial activity |
WO2008071749A3 (en) * | 2006-12-12 | 2008-07-31 | Morphosys Ag | Internalization |
US8394379B2 (en) | 2003-05-15 | 2013-03-12 | Iogenetics, Llc | Targeted cryptosporidium biocides |
US8703134B2 (en) | 2003-05-15 | 2014-04-22 | Iogenetics, Llc | Targeted cryptosporidium biocides |
US9611323B2 (en) | 2010-11-30 | 2017-04-04 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2869088A1 (en) * | 2002-02-07 | 2003-08-14 | Massachusetts Institute Of Technology | Anti-pathogen treatments |
JP2007523159A (en) * | 2004-02-20 | 2007-08-16 | ジェネシス リサーチ アンド デベロップメント コーポレイション リミテッド | Targeted delivery of RNA interference molecules |
US8080560B2 (en) * | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
US8619257B2 (en) * | 2007-12-13 | 2013-12-31 | Kimberley-Clark Worldwide, Inc. | Recombinant bacteriophage for detection of nosocomial infection |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997029185A1 (en) * | 1996-02-06 | 1997-08-14 | Phagen Ab | Recombinant phages |
WO1998005344A1 (en) * | 1996-08-05 | 1998-02-12 | Brigham And Women's Hospital, Inc. | Bacteriophage-mediated gene therapy |
WO1999010485A1 (en) * | 1997-08-29 | 1999-03-04 | Selective Genetics, Inc. | Methods using phage display for selecting internalizing ligands for gene delivery |
WO2000053163A1 (en) * | 1999-03-05 | 2000-09-14 | Werner Lubitz | Bacterial ghosts as carrier and targeting vehicles |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB829266A (en) | 1957-03-20 | 1960-03-02 | Biogena | A method of manufacturing bacteriophages in solid dry form |
JP3771253B2 (en) | 1988-09-02 | 2006-04-26 | ダイアックス コープ. | Generation and selection of novel binding proteins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
IL93982A0 (en) | 1989-04-03 | 1991-01-31 | Purdue Research Foundation | Method for enhancing transmembrane transport of exogenous molecules |
DE59106279D1 (en) | 1990-05-18 | 1995-09-21 | Genentech Inc | NEW PROTEIN POLYCATION CONJUGATES. |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992006191A1 (en) | 1990-09-28 | 1992-04-16 | Protein Engineering Corporation | Proteinaceous anti-dental plaque agents |
AU660629B2 (en) | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
CA2105304C (en) | 1991-03-01 | 2005-10-04 | Arthur C. Ley | Inhibitors of human neutrophil elastase and human cathepsin g |
ES2330052T3 (en) | 1991-03-01 | 2009-12-03 | Dyax Corporation | CHEMICAL PROTEIN THAT INCLUDES MICRO-PROTEINS THAT HAVE TWO OR MORE DISULFURENT BRIDGES AND RELATIONSHIPS OF THE SAME. |
DE4110409C2 (en) | 1991-03-29 | 1999-05-27 | Boehringer Ingelheim Int | New protein-polycation conjugates |
DE4115038A1 (en) | 1991-05-08 | 1992-11-12 | Genentech Inc | NEW CONJUGATES, COMPOSED OF A GLYCOPROTEIN AND A NUCLEIC ACID-BINDING SUBSTANCE |
WO1993000103A1 (en) | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
US5922859A (en) | 1992-02-01 | 1999-07-13 | Boehringer Ingelheim International Gmbh | Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells |
DE4311651A1 (en) | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus for the transport of foreign DNA into higher eukaryotic cells |
JPH08509613A (en) | 1993-04-27 | 1996-10-15 | シンバイオテック・インコーポレイテッド | Method for detecting compounds using chemically modified lambdoid bacteriophage |
DE4335025A1 (en) | 1993-10-14 | 1995-04-20 | Boehringer Ingelheim Int | Endosomolytically active particles |
CA2186962A1 (en) | 1994-04-05 | 1995-10-12 | Richard M. Carlton | Antibacterial therapy with genotypically modified bacteriophage |
EP0767840A2 (en) | 1994-05-30 | 1997-04-16 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Method for introducing foreign matter into higher eukaryotic cells |
DE4418965A1 (en) | 1994-05-31 | 1995-12-07 | Boehringer Ingelheim Int | Transfection of eukaryotic cells with nucleic acid |
GB9412844D0 (en) | 1994-06-27 | 1994-08-17 | Medical Res Council | Improvements in or relating to therapeutic methods |
US5736388A (en) | 1994-12-30 | 1998-04-07 | Chada; Sunil | Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells |
WO1997023608A1 (en) | 1995-12-22 | 1997-07-03 | Chiron Corporation | Compositions and methods for targeting gene delivery vehicles using covalently bound targeting elements |
EP0895534A1 (en) | 1996-04-15 | 1999-02-10 | Nymox Corporation | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
US6054312A (en) | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
-
1999
- 1999-04-09 GB GBGB9908195.2A patent/GB9908195D0/en not_active Ceased
-
2000
- 2000-04-10 DK DK00919042T patent/DK1169063T3/en active
- 2000-04-10 CA CA002372078A patent/CA2372078A1/en not_active Abandoned
- 2000-04-10 JP JP2000610522A patent/JP2002541217A/en active Pending
- 2000-04-10 AT AT00919042T patent/ATE270115T1/en not_active IP Right Cessation
- 2000-04-10 PT PT00919042T patent/PT1169063E/en unknown
- 2000-04-10 ES ES00919042T patent/ES2220451T3/en not_active Expired - Lifetime
- 2000-04-10 WO PCT/GB2000/001350 patent/WO2000061190A2/en active IP Right Grant
- 2000-04-10 DE DE60011880T patent/DE60011880T2/en not_active Expired - Fee Related
- 2000-04-10 US US09/937,872 patent/US6660264B1/en not_active Expired - Fee Related
- 2000-04-10 EP EP00919042A patent/EP1169063B1/en not_active Expired - Lifetime
- 2000-04-10 AU AU39798/00A patent/AU772115B2/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997029185A1 (en) * | 1996-02-06 | 1997-08-14 | Phagen Ab | Recombinant phages |
WO1998005344A1 (en) * | 1996-08-05 | 1998-02-12 | Brigham And Women's Hospital, Inc. | Bacteriophage-mediated gene therapy |
WO1999010485A1 (en) * | 1997-08-29 | 1999-03-04 | Selective Genetics, Inc. | Methods using phage display for selecting internalizing ligands for gene delivery |
WO2000053163A1 (en) * | 1999-03-05 | 2000-09-14 | Werner Lubitz | Bacterial ghosts as carrier and targeting vehicles |
Non-Patent Citations (1)
Title |
---|
LAROCCA D ET AL: "Targeting bacteriophage to mammalian cell surface receptors for gene delivery Äsee commentsÜ." HUMAN GENE THERAPY, (1998 NOV 1) 9 (16) 2393-9. , XP000971367 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002034892A1 (en) * | 2000-10-25 | 2002-05-02 | Intercell Biomedizinische Forschungs- Und Entwicklungs Ag | Modified phage, comprising a non-lytic modification and expressing a kil-gene |
EP1395273A1 (en) * | 2001-05-15 | 2004-03-10 | Page W. Faulk | Targeted delivery of drugs for the treatment of viral infections |
EP1395273A4 (en) * | 2001-05-15 | 2004-08-18 | Faulk Pharmaceuticals Inc | Targeted delivery of drugs for the treatment of viral infections |
US8183208B2 (en) | 2001-05-15 | 2012-05-22 | Faulk Pharmaceuticals, Inc. | Targeted delivery of drugs for the treatment of viral infections |
WO2003000274A2 (en) * | 2001-06-22 | 2003-01-03 | Phage Genomics Inc. | Bacteriophage preparation for the treatment of intracellular bacterial infection |
WO2003000274A3 (en) * | 2001-06-22 | 2004-03-18 | Phage Genomics Inc | Bacteriophage preparation for the treatment of intracellular bacterial infection |
WO2003010316A1 (en) * | 2001-07-24 | 2003-02-06 | Phage Genomics Inc. | Bacteriophage-mediated lysis anthrax bacteria |
WO2003077953A2 (en) * | 2002-03-12 | 2003-09-25 | Phage Genomics Inc. | Bacteriophage composition |
WO2003077953A3 (en) * | 2002-03-12 | 2004-01-08 | Phage Genomics Inc | Bacteriophage composition |
JP2005523943A (en) * | 2002-04-27 | 2005-08-11 | ユニヴァーシティー オヴ ストラスクライド | Virus immobilization and stabilization |
JP2012211135A (en) * | 2002-04-27 | 2012-11-01 | Univ Of Strathclyde | Immobilization and stabilization of virus |
DE10235967B4 (en) * | 2002-08-06 | 2005-09-08 | Bayer Healthcare Ag | Method for identifying substances with antimicrobial activity |
WO2004087924A3 (en) * | 2003-03-31 | 2005-05-26 | Max Planck Gesellschaft | Method for delivery of substances to intracellular microorganisms |
WO2004087924A2 (en) * | 2003-03-31 | 2004-10-14 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for delivery of substances to intracellular microorganisms |
US8394379B2 (en) | 2003-05-15 | 2013-03-12 | Iogenetics, Llc | Targeted cryptosporidium biocides |
US8703134B2 (en) | 2003-05-15 | 2014-04-22 | Iogenetics, Llc | Targeted cryptosporidium biocides |
WO2008071749A3 (en) * | 2006-12-12 | 2008-07-31 | Morphosys Ag | Internalization |
CN101558156B (en) * | 2006-12-12 | 2011-11-23 | 莫佛塞斯公司 | Internalization |
AU2007331484B2 (en) * | 2006-12-12 | 2012-11-15 | Morphosys Ag | Internalization |
US8759087B2 (en) | 2006-12-12 | 2014-06-24 | Morpho Sys AG | Internalization |
US9611323B2 (en) | 2010-11-30 | 2017-04-04 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
US10941215B2 (en) | 2010-11-30 | 2021-03-09 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
DK1169063T3 (en) | 2004-11-01 |
AU3979800A (en) | 2000-11-14 |
WO2000061190A3 (en) | 2001-03-01 |
CA2372078A1 (en) | 2000-10-19 |
ATE270115T1 (en) | 2004-07-15 |
DE60011880D1 (en) | 2004-08-05 |
ES2220451T3 (en) | 2004-12-16 |
AU772115B2 (en) | 2004-04-08 |
JP2002541217A (en) | 2002-12-03 |
US6660264B1 (en) | 2003-12-09 |
GB9908195D0 (en) | 1999-06-02 |
DE60011880T2 (en) | 2005-08-25 |
PT1169063E (en) | 2004-10-29 |
EP1169063A2 (en) | 2002-01-09 |
EP1169063B1 (en) | 2004-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1169063B1 (en) | Treatment of intracellular infection | |
JP4073900B2 (en) | Compositions and methods for treating infections with analogues of indolicidin | |
US7985573B2 (en) | Targeted drug-carrying bacteriophages | |
KR101617790B1 (en) | Engineered Tunable Nanoparticles for Delivery of Therapeutics, Diagnostics, and Experimental Compounds and Related Compositions for Therapeutic Use | |
Vaks et al. | In vivo characteristics of targeted drug-carrying filamentous bacteriophage nanomedicines | |
WO1998007745A9 (en) | Compositions and methods for treating infections using analogues of indolicidin | |
JPH06504267A (en) | Recombinant BPI protein, use of BPI protein and method for producing the protein | |
JP2022101618A (en) | Conditionally active polypeptides | |
JP2004516809A (en) | Molecular transport vehicles for transporting selected compounds to targets | |
Forde et al. | Differential in vitro and in vivo toxicities of antimicrobial peptide prodrugs for potential use in cystic fibrosis | |
KR20080100376A (en) | Agent-enriched nanoparticles based on hydrophilic proteins | |
JP2002502243A (en) | Integrin-targeting vector with transfection activity | |
JP2003530360A (en) | Peptide conjugates for drug delivery | |
Garg | Filamentous bacteriophage: A prospective platform for targeting drugs in phage-mediated cancer therapy | |
WO2003101494A1 (en) | Materials and methods relating to polyions and substance delivery | |
JP2020527556A5 (en) | ||
US6066319A (en) | Drug delivery using terminal complement components | |
EP1174439B1 (en) | Compositions and methods for treating infections using analogues of indolicidin | |
Wang et al. | Expression of scFv‐Mel‐Gal4 triple fusion protein as a targeted DNA‐carrier in Escherichia Coli | |
Alabi et al. | Bioreversible anionic cloaking enables intracellular protein delivery with ionizable lipid nanoparticles | |
Alamgir et al. | Bioreversible anionic cloaking enables intracellular protein delivery with ionizable lipid nanoparticles | |
JP2006517177A (en) | Compositions for transporting therapeutic molecules to the lung and their use for the treatment of lung cancer and disease | |
Yacoby et al. | Targeted Drug-carrying Filamentous Phage Nanomedicines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000919042 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 610522 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2372078 Country of ref document: CA Ref country code: CA Ref document number: 2372078 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 39798/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09937872 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000919042 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000919042 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 39798/00 Country of ref document: AU |